西妥昔单抗联合雷替曲塞三线治疗晚期结直肠癌的效果与安全性分析

Analysis of the efficacy and safety of cetuximab combined with retetroxide in the third-line treatment of advanced colorectal cancer

目的探讨西妥昔单抗联合雷替曲塞三线治疗晚期结直肠癌的效果与安全性。方法选取2016年10月至2019年10月本院收治的104例晚期结直肠癌患者作为研究对象,随机分为对照组与观察组,每组52例。对照组采取常规治疗联合雷替曲塞治疗,观察组采取常规治疗联合西妥昔单抗和雷替曲塞三线治疗,比较两组临床疗效及不良反应发生情况。结果观察组治疗总有效率为46.15%,高于对照组的19.23%,差异有统计学意义(P<0.05)。两组恶心呕吐、肝脏损伤、神经毒性、骨髓抑制、皮肤黏膜反应发生率比较差异无统计学意义。结论西妥昔单抗联合雷替曲塞三线治疗晚期结直肠癌疗效显著,安全性高,值得临床推广应用。

Objective To study the efficacy and safety of cetuximab combined with retetroxide in the third-line treatment of advanced colorectal cancer.Methods 104 patients with advanced colorectal cancer were treated in our hospital from October 2016 to October 2019 were selected as the research subjects,and they were randomly divided into the control group and the observation group,with 52 cases in each group.The control group was treated with conventional treatment combined with retetroxide,while the observation group was treated with conventional treatment combined with cetuximab and the third-line treatment with retetroxide,the clinical efficacy and adverse reactions were compared between the two groups.Results The total effective rate in the observation group was 46.15%,which was higher than 19.23%in the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of nausea and vomiting,liver injury,neurotoxicity,bone marrow transplantation,skin mucosal reactions and other adverse reactions between the two groups.Conclusion Cetuximab combined with retetroxide in the third-line treatment of advanced colorectal cancer has significant efficacy and high safety,and is worthy of clinical promotion and application.